{"id":973605,"date":"2026-06-18T08:35:29","date_gmt":"2026-06-18T12:35:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\/"},"modified":"2026-06-18T08:35:29","modified_gmt":"2026-06-18T12:35:29","slug":"maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\/","title":{"rendered":"MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University"},"content":{"rendered":"
\n

\n
\n Georgia\u2019s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide<\/i>
\n <\/b>\n <\/p>\n

\n CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) — <\/strong>MAIA Biotechnology, Inc. (NYSE American: MAIA) (\u201cMAIA\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the third U.S. clinical site in its Phase 2 THIO-101 expansion trial, Winship Cancer Institute of Emory University (\u201cWinship\u201d), is activated and now enrolling patients. The trial studies MAIA\u2019s lead investigational telomere-targeting agent, ateganosine, as a third-line (3L) treatment for non-small cell lung cancer (NSCLC).<\/p>\n

Matthew Failor, Director of Clinical Operations for MAIA, commented, \u201cWinship is Georgia’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center and is recognized at the forefront of cancer innovation and discovery nationwide. Winship offers a renowned thoracic oncology clinical research program with a proven track record in clinical trial development and conduct. With its premier medical team and extensive body of research, this cancer center is well-suited for our U.S. Phase 2 trial of ateganosine.\u201d<\/p>\n

The principal investigator for the THIO-101 expansion trial at Winship is Ticiana Leal, M.D., a professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine. Dr. Leal\u2019s clinical research focuses on trials involving chemotherapy and immunotherapy agents for lung cancer.<\/p>\n

Dr. Leal commented, \u201cAt Winship, we serve\u00a0the state of Georgia and surrounding\u00a0states where innovation in lung cancer treatment is a broad, underserved need. In Georgia, lung cancer is the leading\u00a0cause of cancer-related deaths, with over 7,300 new cases in 2025. MAIA\u2019s novel ateganosine agent, if approved, could address a significant gap in clinical care for the advanced-stage NSCLC patient population where there are no FDA-approved options available for treatment.\u201d<\/p>\n

THIO-101 is an ongoing Phase 2, open-label trial evaluating ateganosine followed by cemiplimab for NSCLC patients resistant to checkpoint inhibitors and chemotherapy. Parts A and B of the trial have shown strong early efficacy, with some patients showing survival exceeding two years, and now MAIA continues to expand the trial in the U.S.<\/p>\n

\n About Ateganosine<\/b>\n <\/p>\n

Ateganosine (THIO, 6-thio-dG or 6-thio-2\u2019-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2\u2019-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS\/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type\u2013specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.<\/p>\n

\n About THIO-101 Phase 2 Clinical Trial<\/b>\n <\/p>\n

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine\u2019s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo\u00ae<\/sup>) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo\u00ae<\/sup>) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.<\/p>\n

\n About MAIA Biotechnology, Inc.<\/b>\n <\/p>\n

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com<\/a>.<\/p>\n

\n Forward Looking Statements <\/b>\n <\/p>\n

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry\u2019s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cfuture,\u201d \u201cpotential,\u201d or \u201ccontinue,\u201d and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, \u201cMAIA,\u201d \u201cCompany,\u201d \u201cwe,\u201d \u201cour,\u201d and \u201cus\u201d refers to MAIA Biotechnology, Inc. and its subsidiaries.<\/p>\n

\n Investor Relations Contact<\/b>
\n
+1 (872) 270-3518
ir@maiabiotech.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Georgia\u2019s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (\u201cMAIA\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the third U.S. clinical site in its Phase 2 THIO-101 expansion trial, Winship Cancer Institute of Emory University (\u201cWinship\u201d), is activated and now enrolling patients. The trial studies MAIA\u2019s lead investigational telomere-targeting agent, ateganosine, as a third-line (3L) treatment for non-small cell lung cancer (NSCLC). Matthew Failor, Director of Clinical Operations for MAIA, commented, \u201cWinship is Georgia’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center and is recognized at the … <\/p>\n

Continue reading “MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-973605","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Georgia\u2019s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (\u201cMAIA\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the third U.S. clinical site in its Phase 2 THIO-101 expansion trial, Winship Cancer Institute of Emory University (\u201cWinship\u201d), is activated and now enrolling patients. The trial studies MAIA\u2019s lead investigational telomere-targeting agent, ateganosine, as a third-line (3L) treatment for non-small cell lung cancer (NSCLC). Matthew Failor, Director of Clinical Operations for MAIA, commented, \u201cWinship is Georgia’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center and is recognized at the … Continue reading "MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-18T12:35:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0ODg2NyM3NjY3MjY0IzUwMDEyMjI1Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University\",\"datePublished\":\"2026-06-18T12:35:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\\\/\"},\"wordCount\":1158,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0ODg2NyM3NjY3MjY0IzUwMDEyMjI1Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\\\/\",\"name\":\"MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0ODg2NyM3NjY3MjY0IzUwMDEyMjI1Nw==\",\"datePublished\":\"2026-06-18T12:35:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0ODg2NyM3NjY3MjY0IzUwMDEyMjI1Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0ODg2NyM3NjY3MjY0IzUwMDEyMjI1Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\/","og_locale":"en_US","og_type":"article","og_title":"MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University - Market Newsdesk","og_description":"Georgia\u2019s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (\u201cMAIA\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the third U.S. clinical site in its Phase 2 THIO-101 expansion trial, Winship Cancer Institute of Emory University (\u201cWinship\u201d), is activated and now enrolling patients. The trial studies MAIA\u2019s lead investigational telomere-targeting agent, ateganosine, as a third-line (3L) treatment for non-small cell lung cancer (NSCLC). Matthew Failor, Director of Clinical Operations for MAIA, commented, \u201cWinship is Georgia’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center and is recognized at the … Continue reading \"MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-18T12:35:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0ODg2NyM3NjY3MjY0IzUwMDEyMjI1Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University","datePublished":"2026-06-18T12:35:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\/"},"wordCount":1158,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0ODg2NyM3NjY3MjY0IzUwMDEyMjI1Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\/","name":"MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0ODg2NyM3NjY3MjY0IzUwMDEyMjI1Nw==","datePublished":"2026-06-18T12:35:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0ODg2NyM3NjY3MjY0IzUwMDEyMjI1Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0ODg2NyM3NjY3MjY0IzUwMDEyMjI1Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/973605","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=973605"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/973605\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=973605"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=973605"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=973605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}